Global Chronic Pain Market Insights, Forecast and Report 2030

January 11 20:10 2022

DelveInsight’s Chronic Pain Market Insights report provides a thorough understanding of current treatment practices, emerging drugs, Chronic Pain market share of the individual therapies, current and forecasted Chronic Pain market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).


Chronic Pain Overview

Pain as an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage. It may be due to an injury or to the brain’s inability to process pain signals properly. Pain is classified as either acute or chronic. Acute pain is usually severe and short-lived (normally 3 months), and is often the result of a disease that may require ongoing treatment.


Some of the key highlights of the Chronic Pain market report

  • Out of 24,925 respondents (52.2% female, mean age 51.5 years), 15,751 (63.7%) respondents were found to be having pain. Out of this, 2,548 (15.7%) had probable NeP based on the PainDetect, which was 10% of all respondents.
  • Overall, the prevalence of chronic pain was 20.4%, and the prevalence of high-impact chronic pain was 7.4%, but women were more likely to have chronic pain (21.7%) and high-impact chronic pain (8.5%) compared with men (19.0% and 6.3%, respectively).
  • Chronic Pain market companies are included like Pfizer/Eli Lilly and Company, Regeneron/Teva Pharmaceuticals/Mitsubishi Tanabe Pharma Corporation, Allergan [acquired by ABBVie], Stayble Therapeutics, Aptinyx, Lateral Pharma, Eli Lilly and Company, Samumed, and many others.
  • Chronic Pain therapies are included like Vyepti (Eptinezumab-jjmr), Tarlige (Mirogabalin), Fasinumab, Lorecivivint, and many others.


Download sample report–


Chronic Pain symptoms include-

Pain may occur with other symptoms depending on the underlying disease, disorder, or condition. For instance, if the pain is due to arthritis, the patient may experience pain in more than one joint. Chronic pain often leads to signs (e.g lassitude, sleep disturbance, decreased appetite, loss of taste for food, weight loss, diminished libido, constipation), which develop gradually. Constant, unremitting pain may lead to depression and anxiety and interfere with almost all activities. Patients may become inactive, withdraw socially, and become preoccupied with physical health. Psychologic and social impairment may be severe, causing a virtual lack of function.


Chronic Pain Diagnosis include-

Diagnosing chronic pain is not easy, as there are no tools to quantify pain. Diagnosis often involves a series of tests and procedures, as well as a review of symptoms and medical history. There is no way to measure pain objectively. Only the person with chronic pain can describe how much pain he or she is feeling.


Chronic Pain Treatment include-

There are several categories of medications that are used for the treatment of chronic pain. Oral medications include those that can be taken by mouth, such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, opioids, opioid-like agents, or combinations of opioids and non-narcotic analgesics, corticosteroids, antirheumatics/immunological agents, and anticonvulsants.


 Chronic Pain Market Report Scope

  • The report covers the descriptive overview of Chronic Pain, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the Chronic Pain epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Pain is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Chronic Pain market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Pain market.


Chronic Pain Market Companies

  • Pfizer/Eli Lilly and Company
  • Regeneron/Teva Pharmaceuticals/Mitsubishi Tanabe Pharma Corporation
  • Allergan [acquired by ABBVie]
  • Stayble Therapeutics
  • Aptinyx
  • Lateral Pharma
  • Eli Lilly and Company
  • Samumed
  • Sorrento Therapeutics
  • And many others.


Learn More about Key Players working in the domain @


Chronic Pain Therapies

  • Vyepti (Eptinezumab-jjmr)
  • Tarlige (Mirogabalin)
  • Ajovy (Fremanezumab)
  • Fasinumab
  • Lorecivivint (SM04690)
  • And many others


Get detailed information about the pipeline therapies @


Table of content

  1. Key Insights
  2. Report Introduction
  3. Chronic Pain Market Overview at a Glance
  4. Executive Summary of Chronic Pain
  5. Epidemiology and Market Methodology
  6. Disease Background and Overview
  7. Diagnosis of Chronic Pain
  8. Current Treatment
  9. Epidemiology and Patient Population
  10. The United States
  11. EU-5
  12. Japan
  13. Patient Journey
  14. Key Endpoints in Chronic Pain Clinical Trials
  15. Marketed Therapies
  16. Emerging Therapies
  17. Chronic Pain: 7 Major Market Analysis
  18. The United States Market Size
  19. EU-5 Market Size
  20. Japan
  21. Market Access and Reimbursement
  22. Market Drivers
  23. Market Barriers
  24. SWOT Analysis
  25. Unmet Needs
  26. Appendix
  27. DelveInsight Capabilities
  28. Disclaimer
  29. About DelveInsight


Speak to our expert-


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States